Protalix Biotherapeutics Inc Stock TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 185M 55.6B 163M 150M 140M 263M 17.48B 269M 1.8B 698M 8.63B 696M 681M 29.97B | P/E 2026 * |
11.8x | P/E 2027 * | 46x |
|---|---|---|---|---|---|
| Enterprise Value | 185M 55.6B 163M 150M 140M 263M 17.48B 269M 1.8B 698M 8.63B 696M 681M 29.97B | EV / Sales 2026 * |
2.37x | EV / Sales 2027 * | 2.74x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 58 | 30/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 58 | 24/08/2025 |
Shoshi Tessler
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 01/07/2008 |
Aharon Schwartz
BRD | Director/Board Member | 82 | 01/11/2014 |
Dror Bashan
BRD | Director/Board Member | 58 | 30/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 179M | |
| +7.13% | +9.97% | +52.48% | +163.30% | 1,006B | |
| +3.99% | +11.50% | +67.23% | +53.89% | 589B | |
| +4.20% | +17.03% | +36.66% | +86.40% | 430B | |
| +0.99% | +5.11% | +29.26% | +21.27% | 331B | |
| +1.82% | +8.85% | +39.72% | +25.35% | 288B | |
| +0.22% | +6.98% | +32.93% | +39.24% | 285B | |
| +0.73% | +13.51% | -26.95% | -41.57% | 213B | |
| +1.56% | +6.14% | +27.82% | +57.78% | 190B | |
| +3.26% | +3.33% | +20.72% | +65.07% | 154B | |
| Average | +0.72% | +5.96% | +31.10% | +52.30% | 387.31B | |
| Weighted average by Cap. | +0.56% | +5.38% | +40.57% | +77.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 78.3M 23.49B 68.79M 63.38M 59.34M 111M 7.38B 114M 761M 295M 3.64B 294M 288M 12.66B | 67.56M 20.27B 59.36M 54.69M 51.2M 95.87M 6.37B 97.96M 657M 254M 3.14B 254M 248M 10.93B |
| Net income | 15.72M 4.72B 13.81M 12.73M 11.92M 22.31M 1.48B 22.8M 153M 59.21M 732M 59.04M 57.75M 2.54B | 4.07M 1.22B 3.58M 3.3M 3.09M 5.78M 384M 5.91M 39.62M 15.34M 190M 15.3M 14.96M 659M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
